- Home
- Companies
- canada saskatchewan
- drug platform
Show results for
Refine by
Drug Platform Suppliers Serving Saskatchewan
49 companies found
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of ...
based inStanmore, UNITED KINGDOM
Acellera’s mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. In order to fulfill this vision, we work with our customers by becoming a key technology partner, boosting their ...
based inMenlo Park, CALIFORNIA (USA)
Strateos Software, a suite of products to automate and centralize your laboratory. Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery. Our mission is to create new knowledge ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
Exploiting RNA dynamics: RNAs rapidly exchange between a vast array of distinct 3D conformations, each revealing potentially novel binding surfaces. These dynamics are critical to understanding RNA function and fully exploiting its untapped ...
based inTaipei, TAIWAN
Lumosa Therapeutics is a clinical-stage pharmaceutical company dedicating to develop novel therapies and solutions for neurological and oncological diseases with urgent unmet medical need. Besides of using Lumosa's own technology platform in drug ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action. Destiny Pharma’s XF platform has advantages over traditional ...
based inEstuary Banks, UNITED KINGDOM
For over 35 years, Powder Systems Limited (PSL) has been at the forefront of designing and engineering advanced technology to support process development. We are a globally recognised, award-winning business with expertise in pharmaceutical and ...
The MSR™ MicroSphere Refiner is a cGMP piece of equipment that allows drug developers and manufacturers to complete a wide range of aseptic processes with their microspheres at various scales. It is a one-of-its-kind solution has been ...
based inSan Clemente, CALIFORNIA (USA)
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. At Glaukos, our focus is to develop and lead the ...
based inCambridge, MASSACHUSETTS (USA)
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research ...
Analyze and prioritize based on the frequency, severity, and potential impact of signals to deliver the highest level of drug safety. ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
Once a target is identified the various effects of the drug can be measured. This involves all read-outs we use during the biomarker validation but instead of looking at the effect of various candidates we focus on one component. As the tumor ...
based inNY, NEW YORK (USA)
As a global Contract Research Organization (CRO), headquartered in New York, USA, Alfa Chemistry has served the pharmaceutical and biotechnology industries for years. Today, Alfa Chemistry is specialized in organic chemistry, material chemistry, and ...
Drug Research Service Platforms: Due to Alfa Chemistry's deeply ingrained research and development capabilities, we have been able to advance technologically in both research and development. In addition, we have ...
based inVista, CALIFORNIA (USA)
NOVO has been providing engineering services to medtech, biotech, print-tech, and other technical product companies for the last two decades. We are a company purpose built for developing new products and solving complex hardware and software ...
Device Types: On-body injectors; Autoinjectors; Pen injectors; Prefilled syringes; Insulin pumps; Microneedle array devices; Smart pills; Electroporation-enabled ...
based inBaltimore, MARYLAND (USA)
SilcsBio provides software and services for unlocking the full potential of computer driven drug design. Our algorithms for mapping proteins will provide you with a level of detail you have never before experienced. From our highly accurate free ...
Guess work in drug discovery can be costly and time consuming. Our team is here to remove that for you. With us, your team ...
based inCambridge, MASSACHUSETTS (USA)
Portal Instruments is developing a needle-free drug delivery platform for effortless delivery and a transformed patient experience. Portal’s platform is in development and not available for sale or use. Portal Instruments is focused on needle-free ...
based inBudapest, HUNGARY
Cytocast, an innovative TechBio startup located in Budapest, is at the forefront of data-driven medical technology.The company's primary focus is on integrating extensive multi-omics data with high-performance computing and advanced data science ...
Cytocast is at the forefront of medical technology with its innovative Cytocast Digital Twin Platform™, a pioneering solution in drug development and personalized medicine. At its core is the CYTOCAST DIGITAL ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Many intravenously delivered Active Pharmaceutical Ingredients (APIs) are insoluble or poorly soluble in water. This can be a major hurdle in pharmaceutical development and may cause promising drugs to fail during the development process and may ...
based inBeach Drive, UNITED KINGDOM
Oval aims to bring truly patient-centric autoinjector platforms to market. Founded in 2009 by Matthew Young, Oval takes a different approach, designing from the outside in, ensuring that all patient needs are met. Our team has a wide range of ...
Oval’s philosophy is to design platforms to be customisable for specific patient needs. Going deeper than the immediate cognitive and physical need when delivering a drug, we look at each patient group’s ...
